Retatrutide for Obstructive Sleep Apnea: NEJM Study & USMLE

The New England Journal of Medicine has published a study of retatrutide, an investigational drug given by injection once a week, for the treatment of obstructive sleep apnea (OSA). The journal's announcement does not include results. Any numbers on efficacy or safety have to come from the full article, and this post does not guess at them.

What happened

NEJM released a paper on once-weekly retatrutide in obstructive sleep apnea. The source we have is only a short announcement. It confirms the drug, the weekly dosing schedule, and the condition being studied. It does not give the study design, the number of participants, the comparator, the dose, the endpoints, or any findings.

So we cannot tell you whether the drug reduced breathing events during sleep, how much, or what side effects occurred. If you want those details, read the original paper: NEJM article.

Why it matters

OSA is common, underdiagnosed, and strongly tied to obesity. For many patients, weight gain narrows the upper airway and worsens apneas. Weight loss therefore improves OSA in many patients, and this makes incretin-based drugs a logical area of research.

Retatrutide is described in the literature as a triple agonist acting on the GIP, GLP-1, and glucagon receptors. That is why it is often grouped with the incretin-based weight-loss agents. A weekly injectable studied in a sleep disorder shows how obesity pharmacotherapy is moving from "weight and glucose" toward "weight-related complications." Whether this particular drug works in OSA is something only the full paper can answer.

What to know for the USMLE: OSA and incretin drugs

Even without the trial data, this news gives you a good reason to review OSA. These are high-yield points.

• Pathophysiology: Repeated collapse of the upper airway during sleep, usually from loss of pharyngeal muscle tone, causes apneas and hypopneas despite ongoing respiratory effort. This distinguishes it from central sleep apnea, where respiratory effort is absent.
• Risk factors: Obesity (especially increased neck circumference), male sex, older age, menopause, craniofacial abnormalities, macroglossia (hypothyroidism, acromegaly, Down syndrome), enlarged tonsils (the classic cause in children), alcohol and sedatives.
• Presentation: Loud snoring, witnessed apneas, daytime sleepiness, morning headaches, nonrestorative sleep, poor concentration, nocturia.
• Screening: STOP-BANG questionnaire (snoring, tiredness, observed apnea, pressure, BMI, age, neck, gender) and the Epworth Sleepiness Scale.
• Diagnosis: Polysomnography is the gold standard. It reports the apnea-hypopnea index (AHI), the number of events per hour of sleep. Commonly used thresholds are 5–14 for mild, 15–29 for moderate, and 30 or more for severe disease. Home sleep apnea testing is an option for patients with a high pretest probability and no major comorbidities.
• Complications: Resistant hypertension, atrial fibrillation, other arrhythmias, heart failure, stroke, insulin resistance, pulmonary hypertension with cor pulmonale, and secondary polycythemia from chronic nocturnal hypoxemia.
• Management: First line for moderate to severe OSA is CPAP, which keeps the airway open with positive pressure. Other measures are weight loss, avoiding alcohol and sedatives, positional therapy, and oral appliances. Options for selected patients include hypoglossal nerve stimulation and surgery such as uvulopalatopharyngoplasty.
• Incretin-based drugs, the pharmacology: GLP-1 receptor agonists increase glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and promote satiety through central effects. GIP agonism adds to the insulinotropic effect. Glucagon receptor activation is thought to increase energy expenditure and affect hepatic lipid metabolism. Know these mechanisms for questions on diabetes and obesity drugs.
• Class adverse effects and contraindications: Nausea, vomiting, diarrhea, pancreatitis, gallbladder disease, and delayed gastric emptying (relevant for aspiration risk around anesthesia). A personal or family history of medullary thyroid carcinoma or MEN2 is a classic contraindication for the GLP-1 class. Whether each of these applies to retatrutide specifically should be checked in the study data, not assumed.
• Exam logic: If a vignette describes an obese patient with snoring, sleepiness, and hypertension, the next step in diagnosis is polysomnography. The first-line treatment in moderate to severe OSA is CPAP. Weight loss is a standard part of management in all patients with obesity.

Limitations

The main limitation here is how little we know. The announcement does not describe the study.

• We have no data on efficacy, safety, dose, duration, or participants.
• We do not know whether the study measured AHI, symptoms, or other outcomes, or whether it tested the drug against placebo or another treatment.
• Retatrutide is described as an investigational drug, so this is research and not a treatment recommendation.
• Nothing here applies to an individual patient. Treatment decisions belong to a clinician who knows the patient.

When you read the full paper, check the design, the population (including BMI and OSA severity), the primary endpoint, the size of the effect, the dropout rate, and adverse events. These are the same questions to ask of any trial you meet in Step 2 CK or in practice.

FAQ

What is retatrutide?

It is an investigational once-weekly injectable drug that acts on the GIP, GLP-1, and glucagon receptors. It is not part of standard OSA care, and the announcement we have gives no data on its results.

Does weight loss treat obstructive sleep apnea?

Weight loss can reduce the severity of OSA in many patients with obesity, because less fat around the upper airway means less tendency to collapse. It does not replace CPAP in every patient, and OSA can persist or recur. Standard guidance still centers on diagnosis with polysomnography and treatment tailored to severity.

Will retatrutide appear on the USMLE?

Unlikely by name, because it is investigational. The exam does test OSA diagnosis and management, the AHI, CPAP, complications, and the pharmacology and adverse effects of GLP-1 receptor agonists. The retatrutide study is a useful prompt to review those topics.

Key takeaways

• NEJM published a study of once-weekly retatrutide in obstructive sleep apnea, but the announcement gives no results. Read the full paper before drawing conclusions about efficacy or safety.
• For the USMLE, focus on OSA basics: risk factors, STOP-BANG, polysomnography and AHI, complications, and CPAP as first-line therapy for moderate to severe disease.
• Review the mechanisms and adverse effects of incretin-based drugs (GLP-1, GIP, glucagon receptor), including pancreatitis, gallbladder disease, and the MTC/MEN2 contraindication.